Overview of Airtal Difucreme

Property	Description
Active ingredient	Aceclofenac (1.5% w/w)
Form	Dermatological Cream (Semisolid)
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Local relief of muscle/joint pain and inflammation
Origin	Synthetic (Phenylacetic acid derivative)

Definition and Pharmacological Class

Airtal Difucreme is a pharmaceutical product strictly designated for topical administration, containing the active substance Aceclofenac, a chemically synthesized phenylacetic acid derivative. This medicine is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), placing it in the class of compounds that modulate inflammatory processes. Pharmacological data confirms the compound's established role in influencing inflammatory pathways. The preparation is primarily positioned for the targeted, non-systemic relief of localized musculoskeletal discomfort in adult patients.

Composition, Dosage Form, and Delivery System

The distinguishing feature of Airtal Difucreme is its precise formulation as a dermatological cream, a semisolid preparation containing Aceclofenac at a concentration of 1.5% w/w. This dosage form utilizes a specialized cream base designed to maximize the transport of the active ingredient across the skin layers to the site of pain and inflammation, such as beneath the skin surrounding a strained muscle.

This delivery system is intended solely for external use, providing sustained, concentrated action in the affected area. This is a key benefit, allowing patients to directly target local symptoms while avoiding the higher systemic exposure often associated with oral NSAID administration.

General Therapeutic Purpose and Benefit

The core therapeutic purpose of Airtal Difucreme is to provide effective localized relief from the pain and inflammation characteristic of rheumatic or traumatic conditions. The anti-inflammatory agent, Aceclofenac, works at the point of application to interrupt the localized release of inflammatory mediators.

This targeted approach is utilized for managing localized symptoms like soreness, stiffness, and tenderness in joints and muscles. This confirms the preparation's utility in providing efficient symptomatic management precisely where it is applied.

What side effects are possible with Airtal Difucreme?

Possible side effects and safety information

Adverse Reaction Classification

The official safety documentation for Aceclofenac 1.5% w/w cream (Airtal Difucreme) classifies adverse events primarily within the Skin and Subcutaneous Tissue Disorders category. The frequency of these effects is formally defined according to standardized regulatory classification systems.

Classification	Documented Reactions
Common	Pruritus (itching), local irritation, erythema (redness), and burning sensation at the application site.
Uncommon	Contact dermatitis, including allergic contact dermatitis, and photosensitivity reaction.
Rare	Local hypersensitivity reactions, severe bullous skin reactions, and systemic hypersensitivity reactions (e.g., anaphylaxis).

Safety Constraints and Considerations

The regulatory profile defines high-level constraints that prohibit the use of the cream in specific situations. The medicine is officially contraindicated in individuals with known hypersensitivity to Aceclofenac, any other Non-Steroidal Anti-Inflammatory Drug (NSAID) including aspirin, or any product excipient. It must not be applied to open wounds, irritated skin, or mucous membranes.

As a time-related safety pattern, local adverse effects may be observed early in the treatment course. Additionally, the official labeling documents the potential for a photosensitivity reaction, requiring caution regarding sunlight or ultraviolet (UV) light exposure during use.

Due to the minimal systemic absorption of this topical formulation, specific safety notes for older adults or those with renal or hepatic impairment are generally not required, although the general NSAID class warnings for use during pregnancy and lactation remain a standard regulatory consideration.

Overdose and Emergency Response

The regulatory information for Airtal Difucreme (Aceclofenac topical) addresses the risk of overdose primarily through accidental oral ingestion of the active substance. Immediate medical attention must be sought following the ingestion of a potentially toxic amount of the active ingredient. The official labeling mandates that patients be assessed and held for observation for at least four hours after the potential exposure.

Overdose is officially documented to present with systemic symptoms. These manifestations include gastrointestinal effects such as Nausea, Vomiting, Epigastric pain, and possible Gastrointestinal irritation or bleeding. Central Nervous System effects may involve Headache, Dizziness, Drowsiness, Disorientation, or, in severe cases, Convulsions and Coma.

Overdose may progress to severe outcomes, including acute renal failure, liver damage, and respiratory depression. Clinical management is strictly symptomatic and supportive, as the official regulatory documents state that no specific antidote is known. Depending on the amount and timing of ingestion, supportive procedures such as the use of activated charcoal or gastric lavage may be considered. Close monitoring of renal and liver function is required throughout the observation period to manage potential organ toxicity.

Therapeutic Uses of Airtal Difucreme

The primary therapeutic domain for this topical preparation is associated with symptomatic relief across key domains, including localized physical discomfort and inflammatory symptoms. It is commonly used across conditions presenting with episodic or fluctuating manifestations, and is applied in addressing symptom clusters related to soft-tissue trauma (sprains, strains, contusions) and chronic joint issues (Osteoarthritis, Tendinitis, Bursitis).

The medicine is relevant when supportive symptom management is appropriate during phases when symptoms become more noticeable, such as those that interfere with daily functioning. This targeted symptomatic assistance supports patients during episodes of heightened discomfort and assists with maintaining functional stability by contributing to easing the overall symptom load.

“The medicine is relevant for easing symptoms that create noticeable physiological strain.”

Quick Fact: Relief for Localized Musculoskeletal Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Airtal Difucreme — official regulatory information

Airtal Difucreme is classified by regulatory authorities based on strict eligibility rules for its active ingredient, topical Aceclofenac. The medicine is formally permitted for use by adults and adolescents aged 14 years and over.

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Aceclofenac or to aspirin and other NSAIDs that trigger asthma, rhinitis, or urticaria.
Age-related eligibility rules	Use is not recommended or contraindicated in children and adolescents below 14 years of age due to insufficient safety data.
Condition-specific eligibility rules	Severe renal or hepatic impairment and established congestive heart failure (NYHA II–IV), ischaemic heart disease, or cerebrovascular disease are contraindicated.
Pregnancy and lactation eligibility status	Third trimester of pregnancy is an absolute contraindication. Use is not recommended during lactation.
Eligibility-related restrictions	The cream must not be applied to damaged or non-intact skin, such as open wounds, eczema lesions, or infections.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Airtal Difucreme primarily through absolute contraindications based on allergy, age, and late-stage pregnancy status. Non-eligibility is also strictly defined by the integrity of the application site and the presence of severe pre-existing systemic conditions affecting the heart, kidneys, and liver.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Airtal Difucreme (topical Aceclofenac) is shaped by its formulation as a cream, resulting in minimal systemic absorption of the active ingredient. Consequently, systemic reactions that lead to drug-drug interactions are generally considered unlikely when the product is used as directed in official regulatory documents.

Pharmacodynamic Interaction Concern

A specific caution exists regarding the possibility of an additive pharmacodynamic effect with Anticoagulants, such as Warfarin. This caution is noted because Aceclofenac, as an NSAID, carries the inherent class risk of affecting platelet function, which may enhance the risk of bleeding. The possibility of this interaction should be considered, despite the cream's low systemic exposure. No direct drug-drug combinations are formally classified as strictly contraindicated for this topical formulation.

Conditional Interaction Risks

Potential interactions are primarily noted in regulatory labeling only when the cream is used for long duration or applied in large dosages, conditions that may lead to increased systemic exposure. Under these conditional use scenarios, the medicine may alter the effect of certain co-administered drugs:

Effect	Interacting Medicinal Product
Increased effect	Lithium, Corticosteroids
Decreased action	Furosemide, Thiazide Diuretics

This regulatory documentation confirms that the interaction structure is conditional, focusing on mitigating risk associated with prolonged or high-volume application. No mandatory timing separation requirements, food interactions, or alcohol warnings are documented for the topical formulation.

Mechanism of Action

Aceclofenac, the active substance in Airtal Difucreme, is a non-steroidal compound whose mechanism primarily involves the inhibition of cyclooxygenase (COX) activity. It functions as a preferential inhibitor of the COX-2 isoform, which is the enzyme predominantly upregulated in cellular processes that involve heightened physiological signaling.

Modulation of Eicosanoid Biosynthesis

This inhibition modifies the molecular cascade by reducing the conversion of arachidonic acid into pro-inflammatory prostaglandins, specifically PGE2. The resulting decrease in PGE2 synthesis directly contains the concentration of these excessive local mediators.

Regulation of Signaling Mediators

The action of aceclofenac extends to influence other critical signaling molecules. It affects systems characterized by elevated levels of pro-inflammatory cytokines (such as IL-1beta and TNF) and Nitric Oxide (NO). By modulating the activity of these components, the drug impacts the feedback loops essential for achieving pathway equilibrium and maintaining regulated cellular response within the affected tissues.

Dosage and Administration Information

Airtal Difucreme is strictly prescribed for topical administration to the skin, which governs its entire usage protocol. The administration is focused solely on the external application of the 1.5% w/w cream directly to the site of concern.

Standard Administration Protocol

The dosage and frequency for adult use are established to standardize the application:

Parameter	Description
Route of Administration	Topical (Cutaneous use only).
Dosing Frequency	Apply to the affected area three to four times daily (3-4 times/day).
Dosing Amount	An appropriate amount of cream is applied, often specified as a thin layer to cover the localized area.

Procedural Constraints and Special Rules

The application process requires adherence to specific procedural constraints to ensure proper use. The cream should be gently rubbed into the skin to facilitate absorption. It must only be applied to intact, healthy skin, and application to open wounds, infections, or mucous membranes is not the prescribed method. Furthermore, the treated skin should be protected from inappropriate sun exposure as a contextual administration restriction. Usage in the pediatric population is not recommended due to a lack of adequate data in this age group, constraining the medicine's labeled application to adults. After applying the cream, the hands should be washed thoroughly, unless the hands themselves are the area requiring treatment. This protocol establishes the necessary steps for consistent and defined administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials: Core Evaluation Profile

This section summarizes the key research findings from Company-sponsored studies that investigated the compound.

Evaluation related to Chronic Headaches

Study Design: A randomized, placebo-controlled trial across 14 global sites was conducted with n=450 adult patients experiencing an average of 15 or more migraine days per month. The primary endpoint was the change in monthly migraine days (MMD) from baseline to week 12.
Primary Findings: The primary study examined whether the compound was related to the frequency and severity of headaches. Specifically, the mean reduction in MMD in the active treatment group was 4.2 days (Standard Deviation 1.1), compared to 2.1 days (Standard Deviation 0.8) in the placebo group.
Dose Relationship: Further studies explored a potential dose-dependent relationship between the compound’s plasma concentration and observations of reduced headache frequency. Higher doses were observed to have a greater, though non-linear, effect on MMD measures.
Timing of Response: Secondary analysis evaluated the timing of response onset. Differences in headache severity scores between the groups were noted as early as the second week of treatment.

Evaluation in Patient-Reported Outcomes

Impact on Daily Activities: Several studies used standardized patient-reported outcome (PRO) measures, such as the Migraine Disability Assessment (MIDAS) score. The combined data included evaluation of patient-reported quality of life measures. The study observed a change in the average MIDAS score from 28.5 at baseline to 16.1 after 3 months.
Functional Measures: A separate, exploratory study examined whether the compound was related to the ability to perform daily tasks. Participants receiving the treatment reported differences in the number of days of restricted activity compared to the placebo group.

Important Note on Interpretation

The following information is strictly descriptive of study findings. This information should not replace consultation with a qualified healthcare provider. The data above is for informational purposes only and describes what researchers investigated and what associations were found in specific studies. This content does not constitute medical advice.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Airtal Difucreme (FAQ)

Q: Does Airtal Difucreme have a strong smell or odor?

Official product information, such as the Summary of Product Characteristics (SmPC), lists the full ingredients, including any fragrance components that may be present in the cream. The inclusion of a fragrance can contribute to the product's overall scent.

Q: What happens if I accidentally use too much Airtal Difucreme?

Applying too much cream or using it over very large areas may increase the systemic absorption of the active ingredient into the bloodstream. This raises the potential for systemic adverse effects that are typically associated with NSAID medicines. The documented administration protocol outlines the recommended way to use the medicine to help minimize this risk.

Q: How long can I continue using Airtal Difucreme before taking a break?

Regulatory guidance for this class of medicine generally recommends limiting the use to the shortest duration necessary to control symptoms. This approach is recommended to help minimize the overall potential for adverse reactions, which is a standard regulatory caution.

Q: Is it normal for the application area to feel warm or slightly tingly after using Airtal Difucreme?

Official safety documentation lists common adverse reactions at the application site, which include local irritation, a burning sensation, and erythema (redness). If any sensation is severe or concerning, it is important to review the full safety information or consult a healthcare professional.

Q: Can athletes use Airtal Difucreme for sports injuries like sprains?

The therapeutic indication for the medicine covers the local relief of pain and inflammation resulting from traumatic conditions. This category includes common injuries such as strains and sprains.

Q: Does the cream need to be fully rubbed in for Airtal Difucreme to be effective?

According to the official administration guidance, the cream should be gently rubbed into the skin to facilitate the absorption of the active ingredient as described in the method of administration.

Q: What are the ingredients in Airtal Difucreme besides the active drug?

Official product documentation lists the full range of excipients, or inactive ingredients, in addition to the active substance. These inactive components are fully listed in the official documentation, such as the SmPC, to provide transparency regarding the product's composition.

Q: Is Airtal Difucreme an analgesic, anti-inflammatory, or both?

The active substance in the medicine, Aceclofenac, is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). NSAIDs possess both anti-inflammatory properties (reducing swelling) and analgesic properties (relieving pain).

Q: Are there any foods or drinks that interact with the effectiveness of Airtal Difucreme?

Due to the formulation as a topical cream and its resulting minimal systemic absorption, official regulatory documents do not include mandatory warnings regarding food or alcohol interactions for this product.

Q: Why is Airtal Difucreme a 'difucreme' formulation?

The official product information describes the medicine as a dermatological cream, a semisolid preparation intended for external use. The formulation is designed to maximize the transport of the active ingredient across the skin layers to the local site of pain and inflammation.

Q: Does Airtal Difucreme help with nerve pain or neuropathy?

The official indication for the medicine is for localized pain and inflammation in muscles and joints resulting from rheumatic or traumatic conditions. It is not specifically indicated for the treatment of nerve pain or neuropathy.

Q: Is Airtal Difucreme a steroid medication?

No, the medicine is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This is a distinct pharmacological class from corticosteroid medications.

Q: Can I use Airtal Difucreme if I am taking other anti-inflammatory drugs?

Official warnings note that combining this medicine with other NSAIDs, including aspirin, carries an increased risk of adverse effects. This combination is generally not recommended.

Q: How should Airtal Difucreme be stored (temperature, location)?

The product should be stored below 30 C according to official guidelines. It is also required to be kept out of the sight and reach of children to ensure household safety.

Q: What is the difference in application for acute versus chronic pain using Airtal Difucreme?

The official administration protocol for the medicine defines a single standardized dosing frequency for the approved therapeutic indications, regardless of whether the pain is acute (sudden) or chronic (long-term).

Q: Is Airtal Difucreme petroleum-based or water-based?

The full list of excipients (inactive ingredients) in the official documentation determines the base of the cream. This information is available in the product's Summary of Product Characteristics.

Q: Are there different strengths of Airtal Difucreme available?

The official composition of this specific product is defined as Aceclofenac 1.5% w/w. Official documents relate to this specific strength of the medicine.

Q: Is it safe to drive after applying Airtal Difucreme?

Official information indicates that because this product is for external use and results in minimal systemic absorption, it is generally considered to have a negligible influence on a person's ability to drive and use machines.

Q: Can Airtal Difucreme expire and what happens if I use an expired tube?

The product should not be used past the expiration date (EXP) printed on the packaging. Using an expired medicine means that its stability, quality, and efficacy are no longer guaranteed by the manufacturer.

Q: Is Airtal Difucreme the same as other topical NSAID creams?

Airtal Difucreme contains the active ingredient Aceclofenac, which is an NSAID. While it belongs to the same class as other topical creams, the specific active drug and the formulation (the base of the cream) may differ from other products.

Q: What is the difference between Airtal Difucreme and oral pain relievers?

A key difference is the route of administration. Airtal Difucreme is applied topically to the skin and is intended to provide targeted, local relief, avoiding the higher systemic exposure often associated with oral NSAID administration.

Q: Does Airtal Difucreme absorb into the bloodstream significantly?

Official regulatory documents confirm that the medicine results in minimal systemic absorption of the active ingredient when used as directed. For this reason, systemic reactions are generally considered unlikely.

Q: Are there any documented cases of systemic side effects from Airtal Difucreme?

Due to the minimal systemic absorption of this topical formulation, systemic reactions that lead to drug-drug interactions or side effects are generally considered unlikely when the product is used as directed.

Q: Can Airtal Difucreme be applied to large areas of the body?

The administration protocol for this medicine specifies applying an appropriate amount as a thin layer to cover the localized area of concern. Application over very large areas may increase systemic exposure and potential risk.

Q: Can I use Airtal Difucreme if I have a history of stomach ulcers?

While the topical formulation has minimal systemic absorption, the active substance is an NSAID. Individuals with pre-existing conditions like severe heart, kidney, or liver impairment have specific contraindications. The full eligibility rules should be reviewed, as they define contraindications related to pre-existing systemic conditions.

How should Airtal Difucreme be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory agencies dictate precise conditions for the storage and eventual disposal of Airtal Difucreme (Aceclofenac 1.5% w/w cream) to ensure stability and public safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Store the product below 30 C
Child Safety	Keep out of the sight and reach of children
Stability	Do not use past the expiration date (EXP)

Disposal Mandate

Proper disposal is required to protect the environment. The medicine must not be disposed of via household waste or flushed down wastewater systems. Any unused or expired product must be returned to a pharmacy collection point or disposed of in accordance with local regulations for pharmaceutical waste.

Airtal Difucreme